Search - tctmd.com

Displaying 41 - 60 of 103

Sort: Relevancy | Date

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

Presentation TVT 2016

Updates From SURTAVI in Intermediate-Risk Patients

Presenter: Jeffrey J. Popma

June 16, 2016

News Daily News

研究确定患者使用 Sapien 3 出现新传导异常、需要心脏起搏器置入的预测因素

L.A. McKeown

February 07, 2016

News Daily News

Study Pinpoints Predictors of New Conduction Abnormalities, Pacemaker With Sapien 3

L.A. McKeown

February 07, 2016

Presentation TCT 2015

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Presenter: Martin B. Leon, Neil E. Moat, Patrick W. Serruys

October 11, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

Advertisement

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

More Early Stroke With SAVR Than TAVR in SURTAVI

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

FDA Approves Next-Gen CoreValve Evolut PRO Valve

First Results from the SURTAVI Clinical Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Intermediate-Risk Studies II: Updates From SURTAVI

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Updates From SURTAVI in Intermediate-Risk Patients

研究确定患者使用 Sapien 3 出现新传导异常、需要心脏起搏器置入的预测因素

Study Pinpoints Predictors of New Conduction Abnormalities, Pacemaker With Sapien 3

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Asian TAVR Registry Shows Good Procedural and Clinical Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content